Medicilon congratulated AD16 is officially accepted by CFDA for clinical trial

Recently, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science and South China Center for Innovative Pharmaceuticals’ “Class 1.1 piperazine da ketone chemical drugs” (AD16) was officially accepted by CFDA for clinical trial.

Medicilon was responsible for the pharmacokinetic and safety evaluation of AD16.  The result of preclinical evaluation showed that AD16 is safe and its metabolites are simple.  AD16 has high druggability and development prospects.

AD16 mainly focuses on Alzheimer’s disease.  According to the China Association of Alzheimer’s in 2013, there were about 6 million patients who suffered Alzheimer’s disease in China.  If AD16 were successfully developed, there would be a new treatment for Alzheimer’s disease.